ABVC BioPharma Achieves $150K Milestone in Licensing Strategy, Total Revenue Reaches $846K

ABVC BioPharma, Inc. has announced a $150,000 cash licensing payment from AiBtl BioPharma Inc., marking a significant step in the commercialization of its drug candidates ABV-1504 and ABV-1505 for Major Depressive Disorder and Attention Deficit Hyperactivity Disorder, respectively. This payment is part of a broader licensing agreement and brings ABVC's total licensing revenue to $846,000 across strategic partnerships, reinforcing its capital-efficient, partnership-driven business model.

The company's licensing-first strategy has led to agreements with multiple partners, including AiBtl, ForSeeCon Eye Corporation, and OncoX BioPharma, Inc., focusing on global development and commercialization of its botanical therapeutics. These partnerships not only provide immediate financial benefits but also position ABVC as a leader in CNS-focused botanical therapeutics, addressing a growing global need for alternative treatments.

With a 234% increase in annual revenue and a 77% year-over-year improvement in earnings per share, ABVC's strategy is proving successful. The company's focus on non-dilutive revenue streams through licensing agreements is expected to contribute significantly to its 2025 revenue, offering sustainable long-term value for shareholders and timely therapeutic alternatives for patients worldwide.